Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12311-013-0531-6 http://scihub22266oqcxt.onion/10.1007/s12311-013-0531-6 C4344126!4344126 !24222635     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24222635 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cerebellum 2014 ; 13 (2 ): 248-68 Nephropedia Template TP {{tp|p=24222635 |t=2014. Consensus paper: management of degenerative cerebellar disorders |pdf=|usr=}}{{24222635 }} gab.com Text Consensus paper: management of degenerative cerebellar disorders JO: Cerebellum http://www.kidney.de/pget.php?&tw=1&pmid=24222635 #FOAvip Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation. Twit Text FOAVip Consensus paper: management of degenerative cerebellar disorders ????Cerebellum http://www.kidney.de/pget.php?&tw=1&pmid=24222635 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24222635 #FOAvip English Wikipedia <ref>{{Cite pmid|24222635 }}</ref> Consensus paper: management of degenerative cerebellar disorders #MMPMID24222635 Ilg W ; Bastian AJ ; Boesch S ; Burciu RG ; Celnik P ; Claaßen J ; Feil K ; Kalla R ; Miyai I ; Nachbauer W ; Schöls L ; Strupp M ; Synofzik M ; Teufel J ; Timmann D Cerebellum 2014[Apr]; 13 (2 ): 248-68 PMID24222635 show ga Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation. |Adolescent [MESH] |Adult [MESH] |Animals [MESH] |Anti-Dyskinesia Agents/*therapeutic use [MESH] |Cerebellar Ataxia/*drug therapy/rehabilitation/therapy [MESH] |Child [MESH] |Humans [MESH] |Neurodegenerative Diseases/*drug therapy/rehabilitation/therapy [MESH]Consensus paper: management of degenerative cerebellar disorders (epmc).pdf DeepDyve Pubget Overpricing